A new homeopathic approach to neoplastic diseases: From cell destruction to carcinogen-induced apoptosis

British Homeopathic Journal

Volumn 89, Issue 2, 2000, Pages 78-83

  Montfort, H ^a  

^a Instituto Superior de Medicina Homeopática de Enseñanza e Investigación   (Mexico)

Author keywords

Apoptosis; Cancer complementary medicine; Carcinogens; Clinical cases

Indexed keywords

3 METHYLCHOLANTHRENE; BENZO[A]PYRENE; CARCINOGEN; GUANINE DERIVATIVE; HOMEOPATHIC AGENT; XANTHINE DERIVATIVE;

ADULT; ALTERNATIVE MEDICINE; APOPTOSIS; ASTROCYTOMA; CANCER PALLIATIVE THERAPY; CASE REPORT; CELL DESTRUCTION; CHILD; FEMALE; HERBAL MEDICINE; HOMEOPATHY; HUMAN; LEIOMYOSARCOMA; LUNG CANCER; MALE; NEOPLASM; NUTRITION; REVIEW;

EID: 0034043952     PISSN: 00070785     EISSN: None     Source Type: Journal    
DOI: 10.1054/homp.1999.0364     Document Type: Review

References (43)

1. Murray CJ, Lopez AD. Mortality by causes for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
2. Boyle P. Global burden of cancer. Lancet 1997; 349(Suppl II): 23-36.
3. Ernst E, Cassileth BR. The Prevalence of Complementary/ Alternative Medicine in Cancer. Cancer 1998; 83: 777-782.
4. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 130.
5. Harber DA, Fearon ER. The promise of molecular genetics. Lancet 1998; 351(Suppl II): 1-8.
6. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 18-21.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53.
8. Kandioler D, Foedinger M, Muller MR, Eckersberger F, Manhalter C, Wolner E. Carcinogen-specific mutations in the p53 tumor supressor gene in lung cancer. J Thorac Cardiovasc Surg 1994; 107: 1095-1098.
9. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 132.
10. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351(Suppl II): 9-16.
11. Parker RG. Iatrogenic Carcinogenesis: Clinical Implications. The Cancer Journal 1997; 3(6): 316-327.
12. Mignotte H, Lasset C, Bonadona V, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998; 76(3): 325-330
13. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 132.
14. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology. 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 129.
15. Yang J, Duersken-Huges P. A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage. Carcinogenesis 1998; 19(6): 1117-1125.
16. Soignet SL, Maslak P, Wang ZG, et al. N Engl J Med 1998; 339(19): 1341-1348.
17. Klaassen CD. Casarett & Doull's Toxicology. The basic science of poisons. 5th edn. New York: McGraw-Hill 1996, p. 205.
18. 3 induces NB4 cell apoptosis with down regulation of Bcl-2 expresion and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88(3): 1052-1061.
19. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90(2): 124-133.
20. Gallager RE. Arsenic - New life for an old potion; Editorial. N Engl J Med 1998; 339(19): 1389-1390.
21. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89(9): 3354-3360.
22. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 94.
23. DeVita VT, Hellman S, Rosenberg S. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincot-Raven Publishers 1997, p. 95.
24. Chinnasamy N, Rafferty JA, Margison GP, O'Conor PJ, Elder RH. Induction of O6-alkylguanine-DNA-alkyltransferase in the hepatocytes of rats following treatment with 2-acetaminofluorene. DNA Cell Biol 1997; 16(4): 493-500.
25. Schemerold I, Spath A. Induction of rat liver O6-alkylguanine-DNA-alkyltransferase by bleomycin. Chem Biol Interact 1986; 60(3): 297-304.
26. Rafferty JA, Clarke AR, Sellappan D, Koref MS, Frayling IM, Margison GP. Induction of murine O6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 1996; 12(3): 693-697.
27. Kim HS, Park YW, Kasai H, et al. Induction of E. coli oh8Gua endonuclease by oxidative stress: its significance in aerobic life. Mutation Res 1996; 363(2): 115-123.
28. Sharma K, Srikant CB. Induction of wild-type p53, Bax and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76(2): 259-266.
29. Fiala ES, Sodum RS, Hussain NS, Rivenson A, Dolan L. Secondary nitroalkanes: induction of DNA repair in rat hepatocytes, activation by aryl sulfotransferase and hepatocarcinogenicity of 2-nitrobutane and 3-nitropentane in female F344 rats. Toxicology 1995; 99(1-2): 89-97.
30. Chan CL, Wu Z, Eastaman A, Bresinck E. Induction and purification of O6-methylguanine-DNA-methyltransferase from rat liver. Carcinogenesis 1990; 11(7): 1217-1221.
31. von Hofe E, Kennedy AR. X-ray induction of O6-alkuylguanine-DNA alkyltransferase protects against some of the biological effects of N-methyl-N-nitrosoguanidine in C3H 10T 1/2 cells. Radiation Res 1991; 127(2): 220-225.
32. Stammberger I, Schmahl W, Nice L. The effects of irradiation, N-ethyl-N-nitrosourea or combined treatment on O6-alkylguanine-DNA alkyltransferase activity in fetal rat brain and liver and the induction of CNS tumors. Carcinogenesis 1990; 11 (2): 219-222.
33. Wu Y, Barnabas N, Russo IH, Yang X, Russo J. Microsatellite instability and loss of heterozygotisity in chromosomes 9 and 16 in human breast epithelial cells transformed by chemical carcinogens. Carcinogenesis 1997; 18(5): 1069-1074.
34. Melzer M. Paradox of carcinogens as cell destroyers and cell stimulators. A biochemical hypothesis. Eur J Cancer 1980; 16 (1): 15-22.
35. Hooson J, Grasso P. The effect of water-soluble chemicals on the growth and mitosis of primary newborn rat kidney cells in culture. Toxicology 1977; 7(1): 1-10.
36. Zhu QF. Short-term assay of colon carcinogen-induction of micronuclei and apoptosis by dimethylhydrazine in the mouse colon crypt cells. Chung Hua Chung Liu Tsa Chih 1991; 13 (3): 171-173.
37. Blankenship LJ, Manning FC, Orenstein JM, Patierno SR. Apoptosis is the mode of cell death causes by carcinogen chromium. Toxicol Appl Pharmacology 1994; 126(1): 75-83.
38. Bisgaard HC, Nagy P, Santoni-Rugiu E, Thorgerirsson SS. Proliferation apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. Hepatology 1996; 23(1): 62-70.
39. Casarett & Doull's. Toxicology, The basic science of poisons, 5th edn. McGraw-Hill 1996, p. 920.
40. Ron E, Morin Doody M, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998; 280: 347-355.
41. Travis LB, Holowaty EJ, Bergfeldt H, et al. Risk of leukemia after Patinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340(5): 351-357.
42. Tsuchitani T, Zighelboim J, Beker J, Bonavida B. Potentiation of cytotoxicity against human ovarian cell-lines with combination of sub-toxic concentrations of tumor necrosis factor and adriamycin or cisplatinum. J Cell Pharmacol 1991; 2: 1-11.
43. Lane D. The promise of molecular oncology. Lancet 1998; 351(Suppl II): 17-20.